Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Itopride→

Itopride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
122898-67-3
Molecular formula
C20H26N2O4
Molecular weight
358.4 g/mol
Drug class
Gastrointestinal prokineticdopamine D2 receptor antagonist and acetylcholinesterase inhibitor
Mechanism of action
Combines dopamine D2-receptor antagonism with acetylcholinesterase inhibition. This increases enteric acetylcholine availability and promotes gastrointestinal motility and gastric emptying.
Indications / reported uses
  • Symptomatic treatment of functional dyspepsia and upper gastrointestinal motility disorders where authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3792

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Itopride Environmental Risk Assessment (ERA) (the Itopride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.